The invention comprises a ready to use film dosage form comprising microemulsion of an Active Pharmaceutical Ingredient embedded or immobilized in a thin polymeric matrix as a double microemulsion and a process of making the same. The microemulsion in the film dosage form of this invention is capable of being absorbed through mucosal route. The process of making the film dosage of this invention comprises steps of forming a film forming dispersion containing film forming polymers, excipients and microemulsion of active pharmaceutical ingredient, casting the same in the form of a film and drying the cast of the film being carried out by means of drying conditions that suit to retain stability of the active pharmaceutical ingredient being selected such that drying of the film is achieved retaining the moisture trapped in the microemulsion embedded in the polymeric film.

The invention comprises a ready to use film dosage form comprising microemulsion of an Active Pharmaceutical Ingredient embedded or immobilized in a thin polymeric matrix as a double microemulsion and a process of making the same. The microemulsion in the film dosage form of this invention is capable of being absorbed through mucosal route. The process of making the film dosage of this invention comprises steps of forming a film forming dispersion containing film forming polymers, excipients and microemulsion of active pharmaceutical ingredient, casting the same in the form of a film and drying the cast of the film being carried out by means of drying conditions that suit to retain stability of the active pharmaceutical ingredient being selected such that drying of the film is achieved retaining the moisture trapped in the microemulsion embedded in the polymeric film.

Provided herein is a topical composition for treatment of a hair-loss related condition or disease and related methods for making and using the topical composition. The topical composition generally comprises ebastine dissolved in a solvent. In some exemplary embodiments, the solvent comprises a monohydric aliphatic alcohol and an ester. In some exemplary embodiments, the solvent comprises a polyol.

Provided herein is a topical composition for treatment of a hair-loss related condition or disease and related methods for making and using the topical composition. The topical composition generally comprises ebastine dissolved in a solvent. In some exemplary embodiments, the solvent comprises a monohydric aliphatic alcohol and an ester. In some exemplary embodiments, the solvent comprises a polyol.

Embodiments relate to compositions comprising a prochlorperazine compound and a nasal carrier, including methods for formulating such compositions for pharmaceutical applications, for example, for treating or reducing the incidence of migraine headaches. Additional embodiments relate to articles comprising a prochlorperazine compound and a nasal carrier, including use of such articles as nasal drops or nasal sprays. Further embodiments relate to methods for using such articles, for example, for treating or reducing the incidence of migraines.

Embodiments relate to compositions comprising a prochlorperazine compound and a nasal carrier, including methods for formulating such compositions for pharmaceutical applications, for example, for treating or reducing the incidence of migraine headaches. Additional embodiments relate to articles comprising a prochlorperazine compound and a nasal carrier, including use of such articles as nasal drops or nasal sprays. Further embodiments relate to methods for using such articles, for example, for treating or reducing the incidence of migraines.

Provided herein are methods of preventing, mitigating, decreasing, reversing and/or treating Arrhythmogenic Cardiomyopathy (ACM) in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula I, a compounds of Formula II, or a compound of Formula III (I) (II), (III) wherein R.sup.1, R.sup.2, R.sup.3, n, R.sup.4, R.sup.4a, R.sup.5, m, R.sup.6, R.sup.7, and p are as defined herein.

##STR00001##

Provided herein are methods of preventing, mitigating, decreasing, reversing and/or treating Arrhythmogenic Cardiomyopathy (ACM) in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula I, a compounds of Formula II, or a compound of Formula III (I) (II), (III) wherein R.sup.1, R.sup.2, R.sup.3, n, R.sup.4, R.sup.4a, R.sup.5, m, R.sup.6, R.sup.7, and p are as defined herein.

##STR00001##

Provided herein are methods for pain relief comprising administering to a subject in need thereof a solid oral pharmaceutical composition having an opioid analgesic and an antiemetic. The solid oral pharmaceutical composition may provide for increased pain relief when administered in comparison to administration of solid oral pharmaceutical composition having an opioid analgesic but lacking the antiemetic.

Provided herein are methods for pain relief comprising administering to a subject in need thereof a solid oral pharmaceutical composition having an opioid analgesic and an antiemetic. The solid oral pharmaceutical composition may provide for increased pain relief when administered in comparison to administration of solid oral pharmaceutical composition having an opioid analgesic but lacking the antiemetic.